A

Akanda Corp
NASDAQ:AKAN

Watchlist Manager
Akanda Corp
NASDAQ:AKAN
Watchlist
Price: 0.5288 USD -2.07% Market Closed
Market Cap: 386k USD
Section:
 

Relative Value

AKAN doesn't have a meaningful market cap.

The Relative Value of one AKAN stock under the Base Case scenario is 2.1623 USD. Compared to the current market price of 0.5288 USD, Akanda Corp is Undervalued by 76%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AKAN Relative Value
Base Case
2.1623 USD
Undervaluation 76%
Relative Value
Price
A
Worst Case
Base Case
Best Case

Valuation Multiples

0.5
P/S
P/S
Price to Sales
0.5
vs History
47
vs Industry
75
Median 3Y
1.5
Median 5Y
0.6
Industry
2.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-0.4
Median 5Y
-0.6
Industry
21.4
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-1.5
Median 5Y
-2.3
Industry
16.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-0.9
Median 5Y
-2
Industry
22.8
More Details
0.1
P/B
P/B
Price to Book Value
0.1
vs History
73
vs Industry
76
Median 3Y
0.6
Median 5Y
0.6
Industry
2.2
More Details
Negative
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
32
Median 3Y
-2.5
Median 5Y
-3.4
Industry
2.9
More Details
Negative
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
7
Median 3Y
-9.9
Median 5Y
-13.3
Industry
5.5
More Details
0.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
0.4
vs History
50
vs Industry
55
Median 3Y
0.5
Median 5Y
0.4
Industry
13
More Details
0.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
0.4
vs History
23
vs Industry
53
Median 3Y
-0.2
Median 5Y
-1.5
Industry
16.5
More Details
1.1
EV/OCF
EV/OCF
Enterprise Value to OCF
1.1
vs History
8
vs Industry
53
Median 3Y
-0.4
Median 5Y
-3.4
Industry
15.6
More Details
0.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
0.8
vs History
8
vs Industry
41
Median 3Y
-0.3
Median 5Y
-3.1
Industry
18.7
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
28
Median 3Y
0.6
Median 5Y
0.6
Industry
1.9
More Details

Multiples Across Competitors

AKAN Competitors Multiples
Akanda Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Akanda Corp
NASDAQ:AKAN
385.1k USD 0.5 -0.1 0.4 0.4
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.7 36.7 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
492.8B USD 5.3 19.6 16.1 20.8
CH
Roche Holding AG
SIX:ROG
264.6B CHF 4.3 28 12 14
UK
AstraZeneca PLC
LSE:AZN
220.5B GBP 5.1 31.7 108.8 159.2
CH
Novartis AG
SIX:NOVN
216.5B CHF 4.9 18.9 12 15.5
US
Merck & Co Inc
NYSE:MRK
270.8B USD 4.2 14.2 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.1 15.4 10.7 12.5
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.6B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
UK
A
Akanda Corp
NASDAQ:AKAN
Average P/E: 24.7
Negative Multiple: -0.1 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.7
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
28
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.7
37%
0.9
CH
Novartis AG
SIX:NOVN
18.9
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.4
3%
5.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
A
Akanda Corp
NASDAQ:AKAN
Average EV/EBITDA: 399.9
0.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
12
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
CH
Novartis AG
SIX:NOVN
12
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
10.7
1%
10.7
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
A
Akanda Corp
NASDAQ:AKAN
Average EV/EBIT: 1 712.3
0.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
14
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.5
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5

See Also

Summary
AKAN intrinsic value, competitors valuation, and company profile.
DCF Valuation
AKAN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AKAN stock valuation using valuation multiples.
Wall Street Estimates
AKAN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AKAN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 307,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.